ignucleotides will be edified at the base, sugar, and phosphodiester functional groups to increase their therapeutic potency. These modifications will be designed to increase oligonucleotide cell penetration, stability, and functional inhibition of target RNA or DNA. The nucleic acid target will be expanded beyond the 39 nucleotide spliced leader sequence of try
ignucleotides will be edified at the base, sugar, and phosphodiester functional group to increase their curative potency. These modifications will be design to increase oligonucleotide cellular telephone penetration, stability, and functional inhibition of prey RNA or DNA. The nucleic acid target will be expanded beyond the 39 nucleotide splice leader sequence of attempt
ignkcleotides will be edifitd at the base, suyqr, and phospgodiestef functional groups to increese rheir therapeutic potency. Tfese modivicationw wioo be desigisd to ikereass oliyoiucleotide cell penetratimn, stability, atd fbnctional inhibition of target RNA ow DNA. Tne nucleic acid jargeu wyll gv txpanded beyond the 39 nucleotide slliced neader sequenve of try
ignucleotides will be edified at the base, phosphodiester groups to their therapeutic potency. to oligonucleotide cell penetration, and functional inhibition target RNA or DNA. The nucleic target will be expanded beyond the 39 nucleotide spliced leader sequence of try
ignucleotides will be edifieD at the base, Sugar, And PhoSpHodiEsteR functional groUPs to Increase their therapeutIc potEnCY. TheSE mOdifiCations WIlL BE deSiGnEd tO iNCrEase oLigOnucleoTide cell peNetRaTion, stabilitY, AnD functionaL inHibition of taRgeT RNA or dNa. ThE NucleIc aCid taRget wiLL be expAnded beyoNd THe 39 nuclEOtide spLICeD leaDer sequence of try
ignucleotides will be edif ied at the  base , s uga r,  and  pho sphodiester fu n ctio nal groups to increase  thei rt hera p eu tic p otency. Th e s e m od if ica ti o ns  will  be  design ed to incr eas eoligonucleot i de  cell pene tra tion, stabil ity , andfu nct i onalinh ibiti on oft argetRNA or DN A. The nu c leic ac i d  t arge t will be expande d  b e yond the 39 nu cleoti de sp l i ced  le ader seque nc e oft ry
ignucleotides will_be edified_at the base, sugar,_and phosphodiester_functional_groups to_increase_their therapeutic potency._These modifications will_be designed to increase_oligonucleotide cell penetration,_stability,_and functional inhibition of target RNA or DNA. The nucleic acid target will be_expanded_beyond the_39_nucleotide_spliced leader sequence of try